The authors review the angiopoietin pathway as an alternative for safer and more efficacious anti-angiogenic therapeutics.
Rathin C. Das, PhD
Advertisement
Rathin Das, PhD, MBA, is chief executive officer of Synergys Biotherapeutics, 1945 Arbol Grande, Walnut Creek, CA 94595, rathindas2009@gmail.com
Articles by Rathin C. Das, PhD
Innovative products and a range of indications drive the therapeutic antibody market.
Advertisement
Latest Updated Articles
Angiopoietins: Novel Targets for Anti-angiogenesis TherapyPublished: October 1st 2013 | Updated:
Therapeutic Antibodies in ReviewPublished: February 1st 2013 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharm Weekly News Roundup—Week of Oct. 13, 2025
2
Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D
3
Strategies for Building Tech Talent in the Biopharma Industry (Part 4)
4
Why Product-Specific Strategies Matter in Advanced Therapy Manufacturing (Part 3)
5
